Daewon Pharmaceutical Co., Ltd. (KRX:003220)

South Korea flag South Korea · Delayed Price · Currency is KRW
13,660
-10 (-0.07%)
At close: May 28, 2025, 3:30 PM KST
-5.92%
Market Cap 295.14B
Revenue (ttm) 597.69B
Net Income (ttm) 10.38B
Shares Out 21.43M
EPS (ttm) 486.45
PE Ratio 25.65
Forward PE 23.96
Dividend 300.00 (2.18%)
Ex-Dividend Date Dec 27, 2024
Volume 23,551
Average Volume 53,722
Open 13,700
Previous Close 13,670
Day's Range 13,600 - 13,750
52-Week Range 12,370 - 20,700
Beta 0.47
RSI 56.78
Earnings Date May 15, 2025

About Daewon Pharmaceutical

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a t... [Read more]

Sector Healthcare
Founded 1958
Employees 1,283
Stock Exchange Korea Stock Exchange
Ticker Symbol 003220
Full Company Profile

Financial Performance

In 2024, Daewon Pharmaceutical's revenue was 598.16 billion, an increase of 13.51% compared to the previous year's 526.95 billion. Earnings were 14.21 billion, a decrease of -40.59%.

Financial Statements

News

There is no news available yet.